Deri Edianto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deri Edianto has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Arlinda Sari Wahyuni
Universitas Sumatera Utara
1 shared publication - Ayodhia Pitaloka Pasaribu
Department of Pediatrics, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
1 shared publication Aznan Lelo
Universitas Sumatera Utara
1 shared publication- I Dewa Gede Ugrasena
Department of Paediatrics, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
1 shared publication - Inke Nadia Diniyanti Lubis
Department of Pediatrics Medan North Sumatra 20155 University of Sumatera Utara Faculty of Medicine
1 shared publication - Makmur Sitepu
Department of Obstetric and Gynecology, North Sumatra University, Medan, Indonesia
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (4) , 569-574
Ivermecatin induces cytotoxic effects in SUP-B15 cell line
Background. Glucocorticoids remain the primary treatment for acute lymphoblastic leukemia (ALL) in children. However, glucocorticoid-resistant ALL exhibits increased mortality rates. To overcome resistance and improve management strategies, alternative therapeutic agents are required. Ivermectin (IVM), widely used as an anthelmintic agent, has been reported to possess anticancer properties through various mechanisms. These properties suggest IVM as a potential alternative treatment for ALL. This study aims to evaluate the role of IVM in inducing cytotoxic effects in the ALL cell line SUP-B15. Methods. The ALL cell line SUP-B15 was examined following treatment with IVM at concentrations of 5, 10, and 20 μM. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess cytotoxic effects of IVM, including measurements of optical density, cell inhibition, and cell viability. Results. IVM demonstrated inhibitory effects on SUP-B15 cells starting at a low dose of 5 μM. The half maximal inhibitory concentration (IC50) of IVM was 5 µM, showing an inhibitory effect of 54.18 ± 0.03% (95% confidence interval: 54.11-54.25%; p < 0.001). Treatment with 10 μM IVM demonstrated the most significant inhibitory effect (59.05 ± 0.1%) and the lowest cell viability (40.95 ± 0.01%). Conclusions. IVM holds potential as a promising alternative therapeutic agent for the treatment of ALL.
- 1 September 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (4) , 569-574
Open AccessIvermecatin induces cytotoxic effects in SUP-B15 cell line
Background. Glucocorticoids remain the primary treatment for acute lymphoblastic leukemia (ALL) in children. However, glucocorticoid-resistant ALL exhibits increased mortality rates. To overcome resistance and improve management strategies, alternative therapeutic agents are required. Ivermectin (IVM), widely used as an anthelmintic agent, has been reported to possess anticancer properties through various mechanisms. These properties suggest IVM as a potential alternative treatment for ALL. This study aims to evaluate the role of IVM in inducing cytotoxic effects in the ALL cell line SUP-B15. Methods. The ALL cell line SUP-B15 was examined following treatment with IVM at concentrations of 5, 10, and 20 μM. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess cytotoxic effects of IVM, including measurements of optical density, cell inhibition, and cell viability. Results. IVM demonstrated inhibitory effects on SUP-B15 cells starting at a low dose of 5 μM. The half maximal inhibitory concentration (IC50) of IVM was 5 µM, showing an inhibitory effect of 54.18 ± 0.03% (95% confidence interval: 54.11-54.25%; p < 0.001). Treatment with 10 μM IVM demonstrated the most significant inhibitory effect (59.05 ± 0.1%) and the lowest cell viability (40.95 ± 0.01%). Conclusions. IVM holds potential as a promising alternative therapeutic agent for the treatment of ALL.
- 1 August 2022
- Published by Bentham Science Publishers Ltd. in Current Women s Health Reviews
- Vol. 18 (3) , 1
Sensitivity Level of Placenta Accreta Index (PAI) Score and Placenta Accreta Spectrum (PAS) Stage as Preoperative Diagnostic Tools for Placenta Accreta Spectrum Disorders (PASD) at Haji Adam Malik General Hospital Medan Indonesia
Background: The incidence of Placenta Accreta Spectrum Disorders (PASD) has increased by 10-fold in 50 years along with the number of cesarean sections. Ultrasound examination using Placenta Accreta Index (PAI) score and Placenta Accreta Spectrum (PAS) stage as a predictor of PASD has been used worldwide at the antenatal screening. The high diagnostic value of these tools will help the physician to diagnose PASD early and minimize the rate of maternal neonatal mortality and morbidity. Objectives: To evaluate the value of PAI score and PAS stage in diagnosing PASD. Methods: This study is a diagnostic test study using the medical records of mothers who gave birth at Haji Adam Malik General Hospital Medan Indonesia between September 2017 to September 2020, who were diagnosed preoperatively as placenta previa suspected PASD through ultrasound examination using PAI score or PAS stage. The results of these two diagnostic tests were compared to clinical diagnostic criteria of PASD from The International Federation of Obstetrics and Gynecology (FIGO) with or without histopathological confirmation. Results: Of the 177 placenta previa cases, there were 142 women with PASD (80.2%). The diagnostic values of PAI score with 4.6 as an optimal cut-off point were 75% sensitivity, 83% specificity, 94% positive predictive values (PPV), and 47% negative predictive values (NPV). The diagnostic values of the PAS stage were 90% sensitivity, 83%, specificity, 96% PPV, and 68% NPV. Conclusion: PAI score and PAS stage have a diagnostic value that looks equally good when used as a diagnostic tool for PASD.
- 1 August 2022
- Published by Bentham Science Publishers Ltd. in Current Women s Health Reviews
- Vol. 18 (3) , 1
Sensitivity Level of Placenta Accreta Index (PAI) Score and Placenta Accreta Spectrum (PAS) Stage as Preoperative Diagnostic Tools for Placenta Accreta Spectrum Disorders (PASD) at Haji Adam Malik General Hospital Medan Indonesia
Background: The incidence of Placenta Accreta Spectrum Disorders (PASD) has increased by 10-fold in 50 years along with the number of cesarean sections. Ultrasound examination using Placenta Accreta Index (PAI) score and Placenta Accreta Spectrum (PAS) stage as a predictor of PASD has been used worldwide at the antenatal screening. The high diagnostic value of these tools will help the physician to diagnose PASD early and minimize the rate of maternal neonatal mortality and morbidity. Objectives: To evaluate the value of PAI score and PAS stage in diagnosing PASD. Methods: This study is a diagnostic test study using the medical records of mothers who gave birth at Haji Adam Malik General Hospital Medan Indonesia between September 2017 to September 2020, who were diagnosed preoperatively as placenta previa suspected PASD through ultrasound examination using PAI score or PAS stage. The results of these two diagnostic tests were compared to clinical diagnostic criteria of PASD from The International Federation of Obstetrics and Gynecology (FIGO) with or without histopathological confirmation. Results: Of the 177 placenta previa cases, there were 142 women with PASD (80.2%). The diagnostic values of PAI score with 4.6 as an optimal cut-off point were 75% sensitivity, 83% specificity, 94% positive predictive values (PPV), and 47% negative predictive values (NPV). The diagnostic values of the PAS stage were 90% sensitivity, 83%, specificity, 96% PPV, and 68% NPV. Conclusion: PAI score and PAS stage have a diagnostic value that looks equally good when used as a diagnostic tool for PASD.
- Open Access
- 12 July 2020
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 17 (2) , 414-419
An ethanol extract of Senduduk fruit (Melastoma malabathricum L) inhibits the expression of vascular endothelial growth factor and tumour necrosis factor alpha in HeLa cells
Aim Senduduk fruit (Melastoma malabathricum L) is native to Indomalaya and is believed to possess anticancer activity. This study investigated antiangiogenic and anti-inflammation effects of an ethanolic extract of Senduduk fruit (EESF) on HeLa cells. Methods Cytotoxicity was assayed in HeLa cell cultures exposed to a concentration series of 500-7.8 µg/mL of EESF. IC 50 was determined with a methylthiazol-tetrazolium (MTT) cell viability assay. Antiangiogenic and anti-inflammation activity was evaluated by an immunocytochemical assay of vascular endothelial growth factor (VEGF) and tumour necrosis factor alpha (TNF-α) expression in HeLa cells cultured with 1× or 2× IC 50 or as a control without EESF. Results IC 50 of the EESF was 956 µg/mL. The intensity of VEGF staining indicated moderate expression in HeLa cells in response to IC 50 , weak expression in response to 2×IC 50 , and strong expression in the absence of the EESF. While the intensity of TNF-α staining indicated moderate expression in HeLa cells in response to IC 50 and to the absence of EESF, and weak expression in response to 2× IC 50. ConclusionSenduduk fruit extract inhibited VEGF and TNF-α expression in HeLa cells in a concentration-dependent manner.
- 12 July 2020
- Published by Medical Association of Zenica-Doboj in Medicinski Glasnik
- Vol. 17 (2) , 414-419
Open AccessAn ethanol extract of Senduduk fruit (Melastoma malabathricum L) inhibits the expression of vascular endothelial growth factor and tumour necrosis factor alpha in HeLa cells
Aim Senduduk fruit (Melastoma malabathricum L) is native to Indomalaya and is believed to possess anticancer activity. This study investigated antiangiogenic and anti-inflammation effects of an ethanolic extract of Senduduk fruit (EESF) on HeLa cells. Methods Cytotoxicity was assayed in HeLa cell cultures exposed to a concentration series of 500-7.8 µg/mL of EESF. IC 50 was determined with a methylthiazol-tetrazolium (MTT) cell viability assay. Antiangiogenic and anti-inflammation activity was evaluated by an immunocytochemical assay of vascular endothelial growth factor (VEGF) and tumour necrosis factor alpha (TNF-α) expression in HeLa cells cultured with 1× or 2× IC 50 or as a control without EESF. Results IC 50 of the EESF was 956 µg/mL. The intensity of VEGF staining indicated moderate expression in HeLa cells in response to IC 50 , weak expression in response to 2×IC 50 , and strong expression in the absence of the EESF. While the intensity of TNF-α staining indicated moderate expression in HeLa cells in response to IC 50 and to the absence of EESF, and weak expression in response to 2× IC 50. ConclusionSenduduk fruit extract inhibited VEGF and TNF-α expression in HeLa cells in a concentration-dependent manner.